- Home
- » Tags
- » Pramlintide
Top View
- Pramlintide: Clinical Strategies for Success Hisham A
- PRESS RELEASE Adocia Announces Two New Multi-Hormonal
- Injectables That Lower Glucose
- Therapeutic Class Overview Therapeuticincretin Mimeticsclass Overview & Amylinomimetics
- Semaglutide Subcutaneous Once-Weekly
- Medication Guide SYMLIN
- Pramlintide Improved Glycemic Control and Reduced Weight in Patients with Type 2 Diabetes Using Basal Insulin
- Category Catalog CAS Product Name Description Alias/Synonym Application M.F/Formula M.W/Mr
- Symlin (Pramlintide)
- Albiglutide (Tanzeum) FDA in April, 2014, for Adjunct Treatment of Diabetes Mel- Diabetes Mellitus Is an Expensive Disease in the United States Litus
- Hypoglycemics, Incretin Mimetics/Enhancers Therapeutic Class Review (TCR)
- Therapeutic Class Overview Amylinomimetics
- Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing
- (EMDAC) June 20, 2017
- Reference ID: 4565036
- Incretin Mimetics & Amylinomimetics
- Insulin Pocketcard™ Years Action Insulin Name Onset Peak Effective Considerations Duration
- Pramlintide (PDF)
- Exenatide and Pramlintide: New Glucose-Lowering Agents for Treating Diabetes Mellitus
- Injectable Medications for Diabetes (Non-Insulin)
- Bindex 559..578
- Getting Started on Levemir® Flextouch®
- SYMLIN (Pramlintide Acetate)
- Advances in Therapeutic Peptides Targeting G Protein-Coupled Receptors
- LEVEMIR (Insulin Detemir [Rdna Origin] Injection) Is a Sterile Solution of Insulin Detemir for Use As a Subcutaneous Injection
- Discovery Awaits You at the 81ST Scientific Sessions
- Insulin Aspart for the Treatment of Type 2 Diabetes
- Annual Meeting of Stockholders
- 125469Orig1s000
- Lixisenatide: a New Glucagon-Like Peptide-1 Agonist Christopher W Ho* Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, USA
- Approaches to the Pharmacological Treatment of Obesity
- New Anti-Obesity Drugs on the Horizon
- SOLIQUA 100/33 (Insulin Glargine
- Pharmacy Medical Necessity Guidelines: Symlin (Pramlintide)
- Therapies for Diabetes: Pramlintide and Exenatide
- A Novel Dual-Hormone Insulin-And
- Pramlintide (Symlin)
- Levemir ® (Insulin Detemir Injection) 100 Units/Ml
- PRESS RELEASE Adocia Announces Positive Topline Results for the First
- Burden of Disease in 2013 Type 2 DM Glucose Management Goals
- Pramlintide in the Management of Insulin-Using Patients with Type 2 and Type 1 Diabetes
- TRULICITY Safely and Effectively
- Version 2, February 21St, 2019 Page 1 of 40 The
- Insulin Detemir Levemir®
- Ep 2422807 A2
- Pramlintide | Memorial Sloan Kettering Cancer Center
- Is Glucagon Ready for Prime Time?
- The Role of Counter-Ions in Peptides—An Overview
- FDA-Approved
- Hypoglycemic Glucose Clamp Studies
- Latest Advances in the Management of Diabetes
- The Role of Prandial Pramlintide in the Treatment of Adolescents with Type 1 Diabetes
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER
- SYMLIN (Pramlintide Acetate) Injection for Subcutaneous Use Mcg/Ml) for 60 and 120 Mcg Doses (3)
- Non-Insulin Antidiabetes Treatment in Type 1 Diabetes Mellitus: a Systematic Review and Meta- Analysis
- Ultra-Fast Insulin-Pramlintide Co-Formulation for Improved Glucose
- Ultra-Fast Insulin-Pramlintide Co-Formulation for Improved Glucose Management in Diabetic Rats
- Tresiba™ (Insulin Degludec) Injection / Long- Acting Insulin
- Finger Prickin' Good: New Drugs ‐ Injectables
- Randomized Comparison of Pramlintide Or Mealtime Insulin Added to Basal Insulin Treatment for Patients with Type 2 Diabetes
- TRULICITY Safely and Effectively
- Insulin Glargine and Lixisenatide Injection), for Never Share a SOLIQUA 100/33 Prefilled Pen Between Patients, Even If the Subcutaneous Use Needle Is Changed
- Drug Class Review Newer Drugs for the Treatment of Diabetes Mellitus
- Injectable Antidiabetic Agents Policy #: Rx.01.162
- Adocia Pharma & Biotech 19 April 2018
- Pharmacology/Therapeutics Ii Block Iii Handouts – 2016-17